definiens: , lnu,(b lR S'n 3.1 ( a ), 1.30 ' m ~ rdllily Re'UOilllbie Iif!ICCS . with respecl to a par1iculllr Party, at the ~lcva nt poinl in time . that is consistenl with the IliUIII practice fol]o>".·l'd by that Pllfty . in the exercise of its reasonable xielllirte aoo bu ~ illeS5 judgment n : laLing to other pn : scnption pharmaceuucal products owned or licensed by II or to which, I has exclusive righlS. which have ( lllIU"kct poleolial ] and are lil . stage of development ] or ( product life ] similar 10 the applicable Prodnct, taking into account measun : s of [ patent covclllge ], [ n : lauve safety ] and ( dlkIlCY ], [ product profile }, the [ eompclttiveness ] of the [ marketplace ], the ( proprietary position ] of the [ compound ] or { Prodoo ! ], the [ regulatory strucl\lle ] involved, the [ relalt\'e profitability ] of ! he [ prodUO:::I$J ( iocluding, witbout limu.(lilon, [ pficrn.gJ and ! reimbum : l1Ienl status ] ) ~nd other rclcwlRt facrors . includil1ll wilhoul limitation [ ~(>ffiparati\'e technical, legal, SClcnlt fic ] . and/or [ medical ] factors